Allogeneic vs. Autologous Stem Cell Therapy: From Basic Science to Clinical Applications

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Stem Cells".

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 2795

Special Issue Editors


E-Mail Website
Guest Editor

E-Mail Website
Guest Editor
Centro di Ricerca E. Menni, Fondazione Poliambulanza Istituto Ospedaliero, 25124 Brescia, Italy
Interests: regenerative medicine; placenta; amniotic membrane; mesenchymal stromal cells; secretome; immunomodulation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Mesenchymal stromal cells (MSCs) have been the subject of several basic, pre-clinical, translational and clinical studies for a wide range of diseases, including neurological disorders, cardiac ischemia, diabetes, and bone and cartilage defects, among others. All these MSC-based studies have established that MSCs are safe, although their efficacy and mechanism of action have not been completely established, thus consequently slowing down the progression of clinical studies to phase 2 or 3. Among the still obscure areas that are under intense and active investigation, the variable outcomes of MSC therapy are crucial issues, with several issues identified as critical determinants for MSC response patterns. In light of this, MSC efficacy was shown to be influenced by many factors in both cell preparation and administration to patients, including study design, cell manufacturing techniques, dosing regimen and route of delivery. Moreover, the choice of both the pathology and the patients to be treated can be difficult, often due to conflicting scientific results or inadequate preclinical animal models. Thus, covering all these aspects of MSC-based therapeutic approaches and clinical outcomes, the benefits of allogeneic versus autologous therapy remain a highly debated topic in the MSC field. This Special Issue provides a platform to share cutting-edge research for all aspects of MSC-based regenerative therapy, from basic science to clinical studies, with particular emphasis on allogeneic, autologous and comparative settings.

Prof. Dr. Enrico Ragni
Dr. Antonietta Rosa Silini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mesenchymal stromal cells
  • regenerative medicine
  • immune reaction
  • transplant
  • basic research
  • preclinical studies
  • clinical studies
  • manufacturing processes
  • patient selection

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

21 pages, 2211 KiB  
Article
Secreted Factors and Extracellular Vesicles Account for the Immunomodulatory and Tissue Regenerative Properties of Bone-Marrow-Derived Mesenchymal Stromal Cells for Osteoarthritis
by Enrico Ragni, Carlotta Perucca Orfei and Laura de Girolamo
Cells 2022, 11(21), 3501; https://doi.org/10.3390/cells11213501 - 4 Nov 2022
Cited by 5 | Viewed by 2157
Abstract
Bone-marrow-derived mesenchymal stromal cells (BMSCs) showed therapeutic potential in the treatment of musculoskeletal diseases, including osteoarthritis (OA). Their soluble mediators and extracellular vesicles (EVs), which make up the secretome, suppress immune response, attenuate inflammation and promote cartilage repair. EVs, as well as the [...] Read more.
Bone-marrow-derived mesenchymal stromal cells (BMSCs) showed therapeutic potential in the treatment of musculoskeletal diseases, including osteoarthritis (OA). Their soluble mediators and extracellular vesicles (EVs), which make up the secretome, suppress immune response, attenuate inflammation and promote cartilage repair. EVs, as well as the whole secretome, have been investigated as cell free approaches for OA although, to date, a disease-tailored molecular fingerprint is missing. In this study, soluble mediators and miRNAs were sifted in the BMSCs’ secretome and EVs, respectively, and analyzed in the frame of cell types and factors involved in OA. The majority of identified molecules repress the activation of immune cells and the production of OA-related inflammatory mediators, as well as promote cartilage protection by acting on both chondrocytes homeostasis and extracellular matrix-degrading enzymes. These data provide the molecular ground for the therapeutic potential of BMSCs for regenerative applications for OA and support the use of secretome or EVs as cell-free applications in joint diseases. Full article
Show Figures

Figure 1

Back to TopTop